27.09.2016 • News

Envigo Launches a Science and Technology Advisory Group

Envigo has announced the launch of a dedicated Science and Technology Advisory Group (STAG) to drive forward emerging areas of research and to develop new technologies. The STAG will have a core membership of six to eight representatives from a range of technical disciplines across the company.

The STAG group will run across all business domains of the company – including Pharmaceutical Development, Research Models and Services as well as Crop Protection and Chemicals Testing.

Its assignment will be to sponsor internal programs designed to develop new or improve existing capabilities. Selected external partnerships will also be explored – including collaborations with academic institutions – along with offering science and technology development services to customers, e.g. new screening assays.

Brian Burlinson, deputy chair of the STAG, commented: “We are encouraging our scientists to put forward new projects for funding, acting as an internal innovation incubator, but also, we are going out to market and asking our customers if they have research problems they would like us to develop into commercial solutions. However, it’s not just about today’s problems, as we are also partnering with universities, both on developing new science and offering work placements to graduates… our ethos is to instil a culture of new science that permeates all areas of the business.”

STAG will also take on a longer term role in the process of attracting talented scientists who possess specific, specialized skill sets that mirror scientific and technological projects planned or in development at Envigo.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.